Regulation of cell cycle by MDM2 in prostate cancer cells through Aurora Kinase-B and p21WAF1/CIP1 mediated pathways |
| |
| Affiliation: | 1. Rumbaugh-Goodwin Institute for Cancer Research, Nova Southeastern University, Fort Lauderdale, Florida, United States;2. Pharmacology and Toxicology Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia;3. College of Medicine, Al-Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia;4. College of Pharmacy, Nova Southeastern University, Fort Lauderdale, Florida, United States;1. Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10065;2. Department of Public Health, Weill Medical College of Cornell University, New York, NY 10065;3. Department of Pathology, University of Michigan, Ann Arbor, MI 48109;4. Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109;5. Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215;6. Harvard Medical School, Boston, MA 02215;7. Institute of Pathology, University of Rostock, Rostock, Germany 18057;8. Department of Urology, Weill Medical College of Cornell University, New York, NY 10065;9. Institute for Precision Medicine of Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10065;10. Division of Urology, Beth Israel Deaconess Medical Center, Boston, MA 02215;11. Department of Medicine, Division of Hematology and Oncology, Weill Medical College of Cornell University, New York, NY 10065 |
| |
| Abstract: | Overexpression of MDM2 oncoprotein has been detected in a large number of diverse human malignancies and has been shown to play both p53-dependent and p53-independent roles in oncogenesis. Our study was designed to explore the impact of MDM2 overexpression on the levels of various cell cycle regulatory proteins including Aurora kinase-B (AURK-B), CDC25C and CDK1, which are known to promote tumor progression and increase metastatic potential. Our data from human cell cycle RT2 profiler PCR array experiments revealed significant changes in the expression profile of genes that are involved in different phases of cell cycle regulation in LNCaP-MST (MDM2 transfected) prostate cancer cells. Our current study has demonstrated a significant increase in the expression level of AURK-B, CDC25C, Cyclin A2, Cyclin B and CDK1 in LNCaP-MST cells as compared with wild type LNCaP cells that were modulated by MDM2 specific inhibitor Nutlin-3. In fact, the expression levels of the above- mentioned proteins were significantly altered at both mRNA and protein levels after treating the cells with 20 μM Nutlin-3 for 24 h. Additionally, the pro-apoptotic proteins including p53, p21, and Bax were elevated with the concomitant decrease in the key anti-apoptotic proteins following MDM2 inhibitor treatment. Also, Nutlin-3 treated cells demonstrated caspase-3 activation was observed with an in-vitro caspase-3 fluorescent assay performed with caspase 3/7 specific DEVD-amc substrate. Our results offer significant evidence towards the effectiveness of MDM2 inhibition in causing cell cycle arrest via blocking the transmission of signals through AURKB-CDK1 axis and inducing apoptosis in LNCaP-MST cancer cells. It is evident from our data that MDM2 overexpression probably is the primary cause for CDK1 up-regulation in the LNCaP-MST cells, which might have occurred possibly through activation of AURK-B. However, further studies in this direction should shed more light on the intracellular mechanisms involved in the regulation of Aurora kinase-B and CDK1 axis in MDM2 positive cancers. |
| |
| Keywords: | MDM2 Aurora Kinase-B CDK1 Apoptosis Nutlin-3 |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
